Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Cyclin D1 (CCND1) is vital for cell cycle progression and frequently altered in human cancers.
• The G870A mutation is the most prevalent CCND1 alteration, leading to distinct isoforms (CCND1a and CCND1b).
• Dysregulation of CCND1 isoforms is implicated in various cancers, necessitating deeper mechanistic understanding.

Purpose of the Study:

• To review alterations in the CCND1 gene, focusing on the G870A mutation and its resulting isoforms.
• To elucidate the molecular mechanisms, regulatory elements, and functional roles of CCND1 isoforms in cancer.
• To discuss the clinical significance and therapeutic potential of targeting CCND1 isoforms.

Main Methods:

• Review of existing literature on CCND1 gene alterations, mutations, and isoforms.
• Analysis of the impact of the G870A mutation on CCND1 isoform characteristics.
• Summary of regulatory factors (cis-elements, trans-factors, splicing) influencing CCND1.
• Highlighting functional roles and clinical implications of CCND1 isoforms.

Main Results:

• CCND1 alterations include amplification, overexpression, and mutations, with G870A being most common.
• The G870A mutation generates CCND1a and CCND1b isoforms with distinct characteristics.
• CCND1 isoforms play roles in cell cycle, invasion, and metastasis, and have clinical relevance in prognosis and treatment response.
• Aberrant CCND1 isoforms are significant targets for cancer therapy.

Conclusions:

• The G870A mutation-driven CCND1 isoforms are critical players in cancer development and progression.
• Targeting these aberrant CCND1 isoforms presents a promising strategy for novel cancer therapeutics.
• Further research into CCND1 isoform regulation and function can refine cancer treatment approaches.